Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield NM pharmacy drug list Cover…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - New MexicoPolicy N/A

    2026 Drug List (pharmacy formulary) — Coverage Criteria

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - New Mexico policy alerts

    Know when Blue Cross Blue Shield - New Mexico releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is BCBSNM's 2026 pharmacy drug list describing covered prescription drugs, tier placements, specialty drug handling, and member/provider processes for coverage, prior authorization, step therapy, and exceptions. It applies to members and prescribing providers using BCBSNM pharmacy benefits.

    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    Policy2026 Drug List (pharmacy formulary) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeAnnual update (no material changes)
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug line lists 'PA' and include documentation of indication, dose, and quantity consistent with the drug list to avoid claim denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6member payment tiers
    30/90typical day supply
    3exception decision timeframe (standard)
    manyentries with PA noted
    QL entriesQL entries
    MyPrime.comonline drug list

    Coverage criteria and formulary controls

    General Coverage Criteria

    Covered drugs are those listed on the drug list and are subject to plan-level rules and limits.

    General coverage rules: Drug coverage applies only to drugs shown on the Drug List; drugs not shown are not covered. Coverage may be limited by FDA-approved labeling, recognized evidence-based guidelines, age restrictions, plan exclusions (e.g., cosmetic indications), and benefit design.

    See Drug List online (MyPrime.com or bcbsnm.com) for the most current entries.

    Member payment tiers: Drugs are assigned to member payment tiers (Preferred Generic, Non‑Preferred Generic, Preferred Brand, Non‑Preferred Brand, Preferred Specialty, Non‑Preferred Specialty) which determine member cost‑share.

    Tier placement may vary by plan; verify benefit-specific cost share via MyPrime.com or the member ID card.

    Prior authorization and step therapy: Some medications require prior authorization ('PA') or step therapy ('ST') as indicated on the Drug List; prescribers must submit authorization or step‑therapy exception requests per payer procedures.
    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    Policy2026 Drug List (pharmacy formulary) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeAnnual update (no material changes)
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug line lists 'PA' and include documentation of indication, dose, and quantity consistent with the drug list to avoid claim denial.
    SourceLink
    On This Page
    Coverage criteria and formulary controlsCoding and quantity-limit examplesPrior authorization, step therapy, documentation, and denial riskInitial therapy and administrative initiation rulesStep therapy flags and tableQuantity limits (QL) by product — key-value listSite-of-care and specialty pharmacy guidanceDefinitions and flag glossaryBackground and scope

    PA/ST indicators appear in the Special Requirements column of each drug line; exception/decision timeframes follow payer rules.

    Quantity/dispensing limits: Dispensing limits/quantity limits ('QL') may apply to specific drugs and are enforced per the listed time window; exceeding QL may result in member financial responsibility or claim denial under state law for certain controlled substances.

    A QL indicator on a drug line specifies the maximum amount allowed (e.g., tablets or mL per X days).

    General formulary coverage guidance

    Coverage and restrictions are indicated on each drug line and determine coverage adjudication.

    Formulary listing entries: Each drug entry lists the drug name, formulation/strength, Drug Tier, and Requirements/Limits fields (e.g., PA, QL, SP, AC, ST). Coverage is determined by the listed tier and any stated Requirements/Limits for that product.

    Consult the specific drug line for product‑level administrative controls and limits.

    Hepatitis C antiviral coverage (PA & QL)

    Coverage and administrative stance for hepatitis C direct‑acting antivirals are specified per product.

    Hepatitis C antiviral coverage: Direct‑acting antivirals (examples: EPCLUSA, HARVONI, SOVALDI, VOSEVI, MAVYRET) are listed on the Drug List and require prior authorization when 'PA' is indicated; many formulations also carry quantity limits and may be managed through specialty pharmacy (SP).product‑specific QL as listed

    Clinical eligibility criteria and treatment‑course specifics are not included in this excerpt; follow product line and PA instructions.

    HIV therapy coverage notes

    Antiretroviral agents (HIV) are listed with tier and dispensing limits where applicable.

    HIV antiretrovirals: HIV single‑tablet regimens and component antiretrovirals are covered per the Drug List; many are assigned QL values (e.g., 30 tablets/30 days for several combination agents) and have tier placements (P or NP).product‑specific QL

    If 'PA' appears on the line, prior authorization is required before dispensing.

    Formulary entries with tier and requirements

    Formulary coverage and any product constraints are listed on each drug line and must be met for coverage.

    Per‑product requirements: Each listed drug includes a Drug Tier and may include Requirements/Limits such as QL (quantity limit), PA (prior authorization), SP (specialty pharmacy), or AC (administrative code). Coverage is contingent on meeting the Requirements/Limits shown for that product.

    Providers should review the individual drug line for exact QL values, PA or SP designations.

    Formulary coverage with utilization management

    Certain drug groups have consistent utilization controls across multiple products.

    Insulin QL: Most insulin products are subject to a quantity limit of 100 mL per 30 days as shown on individual insulin lines (applies to listed rapid‑, short‑, intermediate‑ and basal insulins).QL 100 mls/30 days

    See each insulin product line for tier placement and dispensing format.

    GLP‑1 and tirzepatide controls: GLP‑1 agonists and tirzepatide (e.g., OZEMPIC, RYBELSUS, TRULICITY, MOUNJARO) are on the formulary but require prior authorization where 'PA' is indicated and have product‑specific quantity limits (e.g., MOUNJARO QL varies by strength; OZEMPIC QL 1 pen/28 days; RYBELSUS QL varies by strength).PA + product‑specific QL

    Prescribers must obtain PA when 'PA' appears on the drug line.

    Combination oral antidiabetics: Combination agents (e.g., JANUMET, SYNJARDY, TRIJARDY XR) are listed with quantity limits (commonly 30–60 tablets per 30 days) and may have PA noted for specific ER formulations.product‑specific QL

    Refer to the product line for exact QL and any PA requirement.

    Formulary Listings and Controls

    Each drug line shows the product, tier, and any utilization controls that must be satisfied for coverage.

    Formulary listings and controls: Drug lines include product name, strength/form, Drug Tier and Requirements/Limits (PA, QL, SP, AC). Coverage requires adherence to those Requirements/Limits; many specialty and high‑cost products require PA and are managed through specialty pharmacy (SP).

    Examples include PA+QL for oral solutions and specialty injectables (see specific lines).

    Coverage with utilization controls

    Formulary coverage is subject to the utilization controls shown on each drug line.

    Formulary attributes and enforcement: Coverage for a listed product depends on the Drug Tier and meeting any Requirements/Limits (PA, QL, SP). For products marked PA, providers must obtain prior authorization before dispensing; for products marked SP, specialty pharmacy dispensing is required.

    Follow the drug line and payer PA submission procedures when indicated.

    General coverage logic

    Coverage decisions rely on drug‑specific tiering and the Requirements/Limits recorded on the formulary line.

    General coverage logic: Drug entries include Drug Tier and Requirements/Limits fields (PA, QL, SP, AC, ST). Coverage is approved only when the listed Requirements/Limits for that product are met (e.g., obtain PA if 'PA' is present; do not exceed the QL in the specified time window).

    Examples: CIMZIA, ENTYVIO PEN, NUCALA and other biologics carry PA and QL and are routed to specialty pharmacy as indicated.

    General formulary coverage conditions

    Coverage of listed drugs is governed by the product tier and its stated Requirements/Limits. Covered when ALL of the following product‑level conditions are met:

    Formulary control nodes: 1) The drug is listed on the Drug List; 2) The drug is prescribed consistent with FDA‑approved indication or accepted off‑label use where permitted; 3) Any stated prior authorization (PA) is obtained when required; 4) Quantity limits (QL) are not exceeded for the applicable time window; 5) Step therapy (ST) requirements are satisfied or a step exception is granted when ST is indicated.

    Operational compliance with the Requirements/Limits column is required for coverage adjudication.

    Drugs not shown on the list are not covered. Coverage is limited to medications listed on the BCBSNM drug list and is subject to the plan’s rules, FDA labeling, and evidence‑based guidelines. Non‑FDA‑approved drugs, repackaged medications, and certain compounded medications may not be covered; refer to member benefit materials or call the number on the ID card for exceptions and payment verification. Prior authorization requirements are indicated as 'PA' in the Special Requirements column for drugs that need approval before coverage. (See examples: EPCLUSA, HARVONI and other DAAs noted with PA.)

    This excerpt does not include a standalone exclusion list. Absence of a drug or formulation from the printed lines in this extract does not itself establish coverage; drugs not listed on the official drug list are considered not covered unless otherwise authorized. For specific excluded categories (for example, some OTC equivalents or cosmetic uses), consult the full benefit plan materials and the complete drug list online.

    Within the provided extract there are no explicit clinical exclusion statements enumerated. The document segment emphasizes per‑product controls (Drug Tier and Requirements/Limits such as PA, QL, SP, AC or ST) rather than listing conditions or patient populations that are categorically excluded. For any formal exclusion language, refer to the full drug list and member plan documents.

    Coding and quantity-limit examples

    Drug listings (no procedure codes)mixed
    N/AThis excerpt does not list CPT/HCPCS/ICD-10 codes; it lists drug names, formulations, tiers, and requirement/limit annotations.
    Drug list (no explicit billing codes provided)mixed
    NDC/HCPCS not specifiedDocument lists many drug products but does not provide specific billing codes in these chunks.
    Drug list — codes not providedmixed
    NDC/HCPCS not specifiedNo explicit procedure, diagnosis, or billing codes (CPT/HCPCS/ICD-10/NDC) are listed in this document segment; only drug names, tiers, PA/QL/SP attributes are present.
    Quantity limits examples
    AzithromycinQL 60 tablets per 180 days
    ARIKAYCE (amikacin liposome inhalation)QL 28 vials per 28 days
    Itraconazole (Sporanox) capsulesQL 120 capsules per 30 days
    Quantity limits examples
    Generic exampleQL 30 tablets per 30 days (example format)
    Pack exampleQL 28 tablets per 28 days (example format)
    Large-volume exampleQL 720 mls per 30 days
    Other common exampleQL 90 tablets per 30 days
    Quantity limits (examples)
    Linezolid suspension (Zyvox)QL 600 mL per 180 days
    Linezolid 600 mg tabletsQL 56 tablets per 180 days
    Vancomycin capsulesQL 120 capsules per 30 days
    Rifaximin (XIFAXAN) 200 mgQL 9 tablets per 30 days
    Example quantity limits
    Budesonide oral suspension (Eohilia)QL 1800 mL per 90 days
    Deflazacort 6 mg (Emflaza)QL 60 tablets per 30 days
    Transdermal exampleQL 30 patches per 30 days
    Large oral solution exampleQL 1800 mls per 90 days
    Insulin quantity limit
    Insulin products (e.g., HUMALOG, NOVOLOG, TOUJEO, TRESIBA)QL 100 mL per 30 days
    NOVOLOG MIX 70/30 PREFILLQL 100 mL per 30 days
    TOUJEO MAX SOLOSTAR / TOUJEO SOLOSTARQL 100 mL per 30 days
    MOUNJARO quantity limit
    MOUNJARO (2.5 mg strength)QL 4 pens per 180 days
    MOUNJARO (other strengths)QL 4 pens per 28 days
    MOUNJARO requirementPrior Authorization (PA) required as noted in product entry
    RYBELSUS quantity limits
    RYBELSUS 3 mgQL 30 tablets per 180 days
    RYBELSUS 7 mgQL 30 tablets per 30 days
    RYBELSUS 14 mgQL 30 tablets per 30 days

    Prior authorization, step therapy, documentation, and denial risk

    Prior Authorization

    Prior authorization and exception timing

    Prior authorization (PA) is required for certain drugs noted with 'PA' in the Special Requirements column; prescribers must submit PA requests via the number on the member ID card or provider portals and will receive a decision within three business days (standard) or within 24 hours for expedited reviews.

    • PA is indicated next to products in the Special Requirements column (e.g., many specialty, antineoplastic, and inhaled agents).
    • Exception/expedited review timelines: standard = 3 business days; expedited = 24 hours.
    Prior Authorization

    Prior authorization requirement (inhaled/specialty)

    Obtain prior authorization before prescribing or dispensing inhaled and specialty inhalation agents listed with 'PA' and 'SP' (examples include ARIKAYCE, tobramycin nebulized solutions, TOBI PODHALER); failure to obtain PA may result in coverage denial.

    • ARIKAYCE — Requirements/Limits = PA, QL (28 vials/28 days), SP.
    • Tobramycin nebulized solutions and TOBI PODHALER — Requirements/Limits include PA, QL and SP.
    Prior Authorization

    PA required for certain hepatitis C treatments

    Prior authorization is required for selected direct-acting hepatitis C antivirals marked 'PA' (e.g., EPCLUSA, HARVONI, SOVALDI, VOSEVI, MAVYRET); submit PA and adhere to the QL listed per product.

    • EPCLUSA — Requirements/Limits = PA, QL (28 tablets/28 days), SP.
    • HARVONI and other DAAs are listed with PA and product-specific QL.
    Prior Authorization

    Prior authorization required for select specialty/antineoplastic drugs

    Many antineoplastic and specialty oral oncology agents are labeled PA and SP; prescribers must obtain prior authorization and follow specialty pharmacy requirements and QL to avoid claim denial.

    • Examples: abiraterone (Zytiga) — PA, QL (120 tablets/30 days), SP.
    • Numerous oncology agents have PA + QL + SP noted in Requirements/Limits.
    Prior Authorization

    PA required for listed products

    Providers must obtain prior authorization for products annotated 'PA' next to the product line; many listed products require PA before dispensing.

    • The formulary marks PA in the Requirements/Limits column for numerous drugs; claims may be denied without PA.
    • PA applies across therapeutic classes including specialty injectables, oral oncology, and select endocrine/metabolic agents.
    Prior Authorization

    PA required for many specialty/oncology drugs

    Numerous specialty and oncology drugs include 'Requirements/Limits = PA' and require prescriber-submitted prior authorization before dispensing; providers must follow PA processes to prevent denials.

    • Examples throughout the formulary show PA flags for many high-cost specialty/oncology agents.
    • Specific PA criteria are not provided in this excerpt; follow payer PA procedures.
    Prior Authorization

    PA required for select listed drugs

    Prior authorization is required for select products flagged 'PA' in the list (examples include deflazacort formulations and budesonide oral suspension); obtain PA prior to dispensing to avoid coverage restriction or denial.

    • Deflazacort (Emflaza) formulations — Requirements/Limits = PA, QL, SP for multiple strengths.
    • Budesonide oral suspension (Eohilia) — Requirements/Limits = PA, QL (1800 mls/90 days).
    Prior Authorization

    Prior authorization required for select agents

    When 'PA' appears in Requirements/Limits for specified agents (e.g., select metformin ER, MOUNJARO, semaglutide products), prescribers must submit prior authorization and respect the listed quantity limits.

    • MOUNJARO — Requirements/Limits = PA, QL (4 pens/180 days for 2.5 mg; 4 pens/28 days for other strengths).
    • OZEMPIC and semaglutide entries — Requirements/Limits = PA, QL (e.g., 1 pen/28 days for OZEMPIC).
    Prior Authorization

    Prior authorization requirement for listed specialty agents

    Prior authorization is required for multiple specialty endocrine/metabolic agents marked 'PA'; providers must obtain PA before coverage is approved for these specialty agents.

    • Examples: ACTHAR — Requirements/Limits = PA, SP; GALAFOLD — PA, QL (14 capsules/28 days), SP.
    • Follow payer PA submission procedures for specialty endocrine/metabolic therapies.
    Prior Authorization

    Prior authorization required

    Providers must obtain prior authorization for many listed drugs (PA flagged) and ensure any specialty injectables or select oral agents meet PA and QL requirements prior to dispensing.

    • Specialty injectables and select oral agents are commonly annotated PA and QL; claims may be denied without PA.
    • Check each drug line for PA, QL, and SP annotations before ordering/dispensing.
    Prior Authorization

    Prior authorization required for selected specialty and oral solution products

    Prior authorization and quantity limits apply to several specialty oral solutions and high-cost oral products (e.g., QBRELIS lisinopril oral solution is PA with QL 2400 mL/30 days; REPATHA requires PA with QL 6 syringes/28 days); include QL and PA details in submissions.

    • QBRELIS (lisinopril oral solution) — Requirements/Limits = PA, QL (2400 mls/30 days).
    • REPATHA (evolocumab) — Requirements/Limits = PA, QL (6 syringes/28 days).
    • TYVASO — Requirements/Limits = PA, QL (81.2 mls/28 days), SP.
    Prior Authorization

    PA required for listed specialty and selected agents

    Prior authorization is required for many listed specialty agents; providers must obtain PA before dispensing those labeled 'PA' to avoid denial.

    • Multiple PA-marked specialty products are present (e.g., ORENITRAM, TYVASO, UPTRAVI, VERQUVO, VYNDAMAX, NUCALA).
    • Follow PA processes and include QL and SP details on requests.
    Prior Authorization

    Prior authorization required for specified drugs

    Several listed products require prior authorization as indicated on each drug line (examples: NUCALA, TEZSPIRE, XOLAIR, TRIKAFTA, KALYDECO); submit PA and adhere to the stated quantity limits and specialty dispensing requirements.

    • NUCALA — PA, QL (3 pens/28 days for 100 mg auto-injector), SP.
    • TEZSPIRE — PA, QL (1 pen/28 days), SP.
    • TRIKAFTA — PA, QL (56 packets/28 days or 84 tablets/28 days), SP.
    Prior Authorization

    PA required for specific specialty medications

    Prior authorization is required for certain specialty medications annotated with 'PA' (examples include BYLVAY, CIMZIA, ENTYVIO PEN, GATTEX); obtain PA and follow specialty channel rules.

    • BYLVAY — Requirements/Limits = PA, SP.
    • CIMZIA — Requirements/Limits = PA, QL (4 syringes/28 days), SP.
    • ENTYVIO PEN — Requirements/Limits = PA, QL (2 pens/28 days), SP.
    Prior Authorization

    PA + QL for biologics

    Many biologic and specialty injectables are subject to PA and an associated quantity limit per dosing period (e.g., SKYRIZI, TREMFYA, OMVOH); include QL details in PA requests to ensure correct adjudication.

    • SKYRIZI — Requirements/Limits = PA, QL (1 cartridge/56 days), SP.
    • TREMFYA — Requirements/Limits = PA, QL (1 syringe/28 days), SP.
    Prior Authorization

    PA required for select drugs

    Certain products require prior authorization as noted next to the product name (e.g., NUPLAZID, tasimelteon); prescribers must obtain PA before billing or dispensing these agents.

    • NUPLAZID — Requirements/Limits = PA, QL (30 capsules/30 days).
    • Tasimelteon (capsule and oral suspension) — Requirements/Limits = PA, QL (30 capsules/30 days; 158 mls/30 days), SP.
    Step Therapy

    Step therapy exception process

    Step therapy (ST) may require trial of a preferred first-line agent before coverage of ST-designated drugs; prescribers can submit an ST exception request via the number on the member's ID card.

    • If the preferred first-line drug is not appropriate, prescribers may request a step therapy exception.
    • Exception decisions follow the standard/expedited timelines (3 business days / 24 hours).
    Step Therapy

    Step therapy note — ST indicators present but rules not detailed

    This excerpt does not provide detailed step-therapy sequences; some products are marked 'ST' (e.g., AUVELITY, KERENDIA) or flagged SP/AC, but the specific prior-step requirements are in the full policy.

    • AUVELITY and select antidepressant/antipsychotic entries show 'ST' in the list where applicable.
    • Refer to the comprehensive policy for required prior trials and documentation.
    Documentation Required

    Documentation required for PA and QL agents

    Prescriptions for drugs with quantity limits (QL) or PA should include documentation supporting medical necessity and dosing consistent with the listed QL (examples: azithromycin QL 60 tablets/180 days; ARIKAYCE PA with QL 28 vials/28 days).

    • Include indication, dose, and requested quantity/timeframe when submitting PA for QL agents.
    • Examples: azithromycin = QL (60 tablets/180 days); ARIKAYCE = PA, QL (28 vials/28 days).
    Documentation Required

    Submit PA documentation per payer process

    When PA is required (PA noted in Requirements/Limits), providers must submit prior authorization documentation per payer procedures to obtain coverage; include indication, dosing schedule, and quantity information.

    • Follow the payer's PA submission process (call the number on the member ID card or use provider portals).
    • Supporting clinical information will be necessary for adjudication of PA requests.
    Denial Risk

    PA and specialty pharmacy denial risk

    Prior authorization denials or failure to use the specialty pharmacy channel for SP-designated products (e.g., many oncology and biologic agents) may lead to claim denials; prescribers must obtain PA and use specialty dispensing where required.

    • Antineoplastics and many specialty agents are PA + SP — lack of PA or failure to use SP may cause denial.
    • Specialty channel requirements are noted by 'SP' on product lines and should be followed.
    Denial Risk

    Quantity limit denial risk — exceed QL at risk of denial

    Exceeding quantity limits (QL) listed on product lines (e.g., linezolid suspension QL 600 mL/180 days; linezolid 600 mg tablets QL 56 tablets/180 days; vancomycin capsules QL 120 capsules/30 days) may trigger claim denial or require member payment for excess quantity.

    • Linezolid for suspension — QL 600 mL/180 days; 600 mg tablets — QL 56 tablets/180 days.
    • XIFAXAN 200 mg — QL 9 tablets/30 days; 550 mg — QL 126 tablets/365 days.
    • Dispensing beyond DL/QL may result in member responsibility for full cost.
    Denial Risk

    Prior Authorization required — confirm before dispensing

    Claims for drugs marked 'PA' will be subject to prior authorization; failure to obtain PA when required may result in denial — verify the Requirements/Limits field on each drug line before dispensing.

    • The formulary flags PA next to affected products; confirm PA status on the drug line.
    • If PA is required and not obtained, the claim may deny.
    Documentation Required

    Include QL and specialty info on PA/claim submissions

    Include quantity-limit (QL) and specialty (SP) designations on PA/claim submissions — many products list QL (e.g., ORENITRAM 300 tablets/30 days; TYVASO 81.2 mL/28 days) and SP that affect adjudication and dispensing.

    • ORENITRAM — Requirements/Limits = PA, QL (300 tablets/30 days), SP.
    • TYVASO — Requirements/Limits = PA, QL (81.2 mls/28 days), SP.
    • NUCALA — PA, QL (3 pens/28 days for 100 mg auto-injector), SP.
    Billing Rule

    Specialty channel requirements — use SP when indicated

    Specialty-designated products (SP) typically require specialty pharmacy dispensing; failure to use the specialty channel when indicated may result in coverage denial or claim rejection.

    • SP annotation denotes specialty pharmacy handling is required for many biologics and high-cost agents.
    • Examples: NUCALA, TREMFYA, SKYRIZI, many oncology and rare-disease products.
    Denial Risk

    Dispensing beyond limits may incur member cost or legal limits

    Dispensing quantities beyond listed dispensing limits or QL may make the member responsible for the full cost of the excess medication; for controlled substances state law may also prohibit coverage beyond limits.

    • Dispensing beyond QL/DL can result in member financial responsibility.
    • State laws may bar coverage for certain controlled substances dispensed beyond limits.
    Note
    Note
    Note
    Note
    Note
    Note

    Initial therapy and administrative initiation rules

    Initial therapy guidance

    Formulary placement and initial dispensing constraints for initiating therapy.

    Initial dispensing rules: At initiation, prescribers should follow the Drug List line: observe tier placement, obtain prior authorization if 'PA' is listed, and adhere to the QL for initial fills (e.g., 1 pen/28 days for certain GLP‑1s).

    Specific product QL/PA values are shown on each drug line; clinical PA criteria are not included in this excerpt.

    Administrative initial-therapy rules

    Administrative initial‑therapy rules direct the process for coverage when a PA or QL is present.

    PA requirement at initiation: If a product’s Requirements/Limits field lists 'PA', prior authorization must be obtained before the initial dispensation will be covered. The Drug List indicates PA on the product line when commonly required.N/A

    Clinical eligibility specifics for PA are not provided in this excerpt; follow payer PA submission instructions.

    Initial therapy rules (per-product PA/QL)

    Initial coverage for selected products is subject to the per‑product PA and QL shown on the Drug List.

    MOUNJARO initial coverage: MOUNJARO requires prior authorization where 'PA' is indicated and has a product‑specific QL (example: 2.5 mg strength listed as 4 pens per 180 days; other strengths 4 pens per 28 days).PA + QL

    Prescriber must request PA when initiating therapy.

    OZEMPIC/RYBELSUS initial coverage: OZEMPIC and RYBELSUS have PA and product‑specific QLs (e.g., OZEMPIC QL 1 pen/28 days; RYBELSUS QL varies by strength — 3 mg listed 30 tablets/180 days; 7/14 mg 30 tablets/30 days).PA + QL

    Confirm exact QL on the Drug List prior to initial dispensing.

    Titration pack coverage

    Titration packs availability: Titration packs (for example, ORENITRAM, TYVASO DPI, UPTRAVI) are listed and are covered per their Requirements/Limits; titration pack fills are subject to the QL and PA shown on the product line.

    Titration pack QL and PA are shown on the Drug List lines for those products.

    Step therapy / initial therapy controls

    Products annotated with 'ST' may require a trial of preferred alternatives prior to coverage.

    Step therapy controls: When a product line lists 'ST', coverage requires documented trial/failure of one or more specified preferred agents (examples in the extract include AUVELITY and certain antidepressants). Prescribers may submit step therapy exception requests if clinically appropriate.

    Detailed step sequences and acceptable alternatives are defined in the full policy; not present in this excerpt.

    Step therapy flags and table

    Drug / ClassST Flag (Special Requirements)Notes
    General formulary - step therapy program
    ST — indicated when present in Special Requirements
    Exceptions: prescriber or member may request a step therapy exception via the number on the member's ID; decisions issued within 3 business days (standard) or 24 hours (expedited)
    Example drug(s)ST FlagPolicy note
    Azithromycin (various formulations)
    No ST indicated
    Shown with QL (60 tablets/180 days) but no step-therapy sequence described in excerpt
    Example drug(s)ST FlagPolicy note
    Darunavir / other oral antivirals
    No ST indicated
    Entries list PA and QL (e.g., darunavir QL entries) but no prior-step failure sequence is provided in this excerpt
    ProductST / SP FlagNotes
    PALFORZIA (multiple level packs)
    SP (specialty)
    Designated SP and listed by dose levels; step therapy requirements are not specified in these chunks
    Agent / ClassAC FlagNotes
    Selected oral oncology agents (example: tamoxifen)
    AC noted for some agents
    AC flags appear (e.g., tamoxifen Requirements/Limits = AC) but specific step therapy rules are not provided in this segment
    Product examplesAC / SP FlagNotes
    Deflazacort formulations (Emflaza)
    PA, SP noted (entries also show QL)
    Some contraceptives and selected therapies are flagged AC or SP indicating administrative/step edits or program controls must be met prior to coverage
    ProductST FlagNotes
    KERENDIA (finerenone)
    ST noted in Requirements/Limits
    KERENDIA is listed with QL (30 tablets/30 days) and marked ST indicating step therapy applies (detailed step criteria not in excerpt)
    ProductST FlagNotes
    AUVELITY (dextromethorphan HBr–bupropion HCl ER)
    ST noted
    AUVELITY is annotated with ST indicating step therapy requirements must be met prior to coverage per full policy; prescriber must document trials of preferred agents
    RequirementPrescriber actionNotes
    Document trials of preferred agents (when ST applies)
    Submit step therapy exception via the number on the member's ID card or provider portals
    Exceptions are processed within three business days (standard) or 24 hours for expedited/urgent requests; prescriber documentation should support prior trials as defined in full policy

    Quantity limits (QL) by product — key-value list

    Dispensing / quantity limits (overview)
    Dispensing/Quantity limits listQuantity limits vary by drug and are indicated as 'QL' in the Special Requirements column
    Azithromycin exampleQL 60 tablets per 180 days
    ARIKAYCE exampleQL 28 vials per 28 days (PA + SP indicated)
    Itraconazole exampleQL 120 capsules per 30 days
    Tobramycin inhaled examplesQL examples include 280 mL/56 days or 224 capsules/56 days for TOBI PODHALER
    azithromycin — example QL
    AzithromycinQL 60 tablets (example)
    ARIKAYCEQL 28 vials
    Itraconazole (Sporanox)QL 120 capsules
    ARIKAYCE / inhaled aminoglycoside examples
    ARIKAYCE (amikacin liposome)QL 28 vials per 28 days; Prior Authorization (PA) and Specialty (SP) indicated
    Tobramycin nebulized solutions (KITABIS PAK)QL 280 mL per 56 days; PA and SP indicated
    TOBI PODHALERQL 224 capsules per 56 days; SP indicated
    itraconazole (Sporanox) quantity limits
    Itraconazole (Sporanox) capsulesQL 120 capsules per 30 days
    Itraconazole oral solutionQL 1200 mL per 30 days (when listed)
    TOLSURA (itraconazole cap 65 mg)PA required for some formulations
    Tobramycin inhalation QLs
    Tobramycin nebulized solutions (Kitabis Pak)QL 280 mL per 56 days; PA and SP indicated
    Tobramycin (Bethkis)QL 224 mL per 56 days; SP indicated
    TOBI PODHALERQL 224 capsules per 56 days; SP indicated
    abacavir quantity limits
    Abacavir sulfate solution (Ziagen) 20 mg/mLQL 960 mL per 30 days
    Abacavir sulfate tablets 300 mgQL 60 tablets per 30 days
    Abacavir-lamivudine combinationsQL 30 tablets per 30 days
    BIKTARVY quantity limit
    BIKTARVY (bictegravir-emtricitabine-tenofovir AF)QL 30 tablets per 30 days
    Formulation noteListed as QL per product line
    TieringDrug Tier indicated per entry (e.g., P)
    EPCLUSA quantity limit
    EPCLUSA (sofosbuvir-velpatasvir)QL 28 tablets per 28 days; PA and SP indicated
    EPCLUSA pellet packQL 28 packs per 28 days; PA and SP indicated
    Hepatitis C agentsMany require PA and have product-specific QLs
    HARVONI quantity limit
    HARVONI (ledipasvir-sofosbuvir)QL 28 tablets per 28 days; PA and SP indicated
    Pellet pack formQL 28 packs per 28 days; PA and SP indicated
    Hepatitis C agent notePA required where listed
    KALETRA and antiviral examples
    KALETRA (lopinavir-ritonavir) oral solution 400-100 mg/5 mLQL 480 mL per 30 days
    Valganciclovir solutions/tabsVariable QLs as listed per product line
    Other antiviral QLsProduct-specific QLs listed adjacent to each entry
    XOFLUZA quantity limit
    XOFLUZA (baloxavir marboxil)QL 2 tablets per 120 days (therapy pack format)
    Therapy pack notePack-based QLs shown for single-course antiviral packs
    Yearly/long-window QLsSome antivirals use non-30-day windows (e.g., 90 or 120 days)
    YEZTUGO quantity limit
    YEZTUGO - lenacapavir tab 300 mgQL 4 tablets per 365 days
    Yeztugo formulationsAlso available as subcutaneous solution; QL varies by form
    Long-interval QLsSome agents have annual QLs rather than monthly windows
    linezolid suspension QL
    Linezolid suspension (Zyvox) 100 mg/5 mLQL 600 mL per 180 days
    Linezolid 600 mg tabletsQL 56 tablets per 180 days
    Linezolid product noteListed QLs apply to both suspension and tablet forms
    linezolid 600 mg tablets QL
    Linezolid 600 mg tabletsQL 56 tablets per 180 days
    Coverage flagRequirements/Limits indicate QL for tablet strength
    Denial riskExceeding QL may trigger denial per document guidance
    vancomycin capsules QL
    Vancomycin capsulesQL 120 capsules per 30 days
    Vancomycin oral solution (Firvanq)Separate product line with its own QL as listed
    QL enforcementExceeding QL may trigger denial
    rifaximin quantity limits
    Rifaximin 200 mgQL 9 tablets per 30 days
    Rifaximin 550 mgQL 126 tablets per 365 days
    Form-specific QLsDifferent strengths have distinct QL windows (30 days vs 365 days)
    Selected antineoplastic QLs
    Abiraterone acetate (Zytiga)QL 120 tablets per 30 days; PA and SP indicated
    AKEEGA (niraparib tosylate-abiraterone)QL 60 tablets per 30 days; PA and SP indicated
    ALECENSA (alectinib)QL 240 capsules per 30 days; PA and SP indicated
    AKEEGA quantity limit
    AKEEGA (niraparib tosylate-abiraterone)QL 60 tablets per 30 days; PA and SP indicated
    PA/SP noteAntineoplastics commonly list PA and SP along with QL
    Coverage instructionSupporting PA documentation required for adjudication
    ALECENSA quantity limit
    ALECENSA (alectinib) 150 mg capsQL 240 capsules per 30 days
    ALECENSA initiation packInitiation/pack QLs noted per entry
    SP designationSpecialty pharmacy dispensing indicated
    ALUNBRIG quantity limits
    ALUNBRIG (brigatinib) initiation packQL 30 tablets per 180 days; PA and SP indicated
    ALUNBRIG 30 mgQL 120 tablets per 30 days; PA and SP indicated
    Coverage notePA and SP commonly apply to ALUNBRIG formulations
    abiraterone acetate quantity limit
    Abiraterone acetateQL 120 tablets per 30 days; PA and SP indicated
    Zytiga strengths250 mg and 500 mg formulations listed with QL
    Antineoplastic handlingSpecialty pharmacy and PA commonly required
    ALECENSA capsule QL
    ALECENSA (alectinib)QL 240 capsules per 30 days; PA and SP indicated
    Formulation noteCapsule form QL specified per entry
    SP requirementSpecialty pharmacy distribution noted
    BESREMI quantity limit
    BESREMI (ropeginterferon alfa-2b)QL 2 syringes per 28 days; PA and SP indicated
    Specialty handlingProduct requires specialty pharmacy dispensing
    PA instructionPrior authorization required as listed
    BRUKINSA quantity limit
    BRUKINSA (zanubrutinib) 80 mgQL 120 capsules per 30 days; PA and SP indicated
    Other strengths160 mg tab QL 60 tablets per 30 days
    PA/SP noteSpecialty and prior authorization commonly required

    Site-of-care and specialty pharmacy guidance

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Definitions and flag glossary

    Background and scope

    Specialty drugs are high‑cost or complex therapies used to treat conditions such as hepatitis, hemophilia, multiple sclerosis, and rheumatoid arthritis. They may be oral, topical or injectable and some require administration by a health care professional; such products may be managed through specialty pharmacy channels or billed to the medical benefit rather than the pharmacy benefit. Review the drug line for any SP (specialty) designation or site‑of‑care notes which indicate specialty dispensing or medical‑benefit handling.

    The extract contains no explicit ‘Not Medically Necessary’ (NMN) statements. While some agents or categories (for example, products with OTC equivalents or drugs used for cosmetic purposes) may be excluded under plan materials, this excerpt does not set out specific NMN determinations. Coverage decisions are governed by the drug list entries, their Drug Tier, and any listed Requirements/Limits (PA, QL, SP, ST) and by the member’s benefit plan documentation.